RORgammat inverse agonist 35 (Compound 22) is an RORgammat inverse agonist with an IC50 of 1.51 µM. It significantly inhibits Th17 differentiation and pro-inflammatory characteristics in human CD4+ T cells. This compound can be utilized for research on Th17-driven autoimmune diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD).
Target:
Interleukin|||ROR
* VAT and and shipping costs not included. Errors and price changes excepted
